There have been mistakes, yes , especially on the HIV BLA
There have been mistakes, yes , especially on the HIV BLA which I wasn’t happy about at all..it was sloppy . But even if people think certain execs aren’t the best, the evidence is pointing to a Dr B.P. selection as CEO if the rumors are true they want to integrate IncellDx with Cytodyn. If that is one of their objectives it is a flawed decision. The whole point of making a change for several longs would be to have an experienced mid to large Pharma ex exec step in those shoes. That’s not Dr P. By a long shot. Being an expert in CCR5 isn’t the same as running a successful Pharma company . So to some who are pushing for this change , be careful what you ask for..
10
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Transforming Research with AI Technology BD (Becton, Dickinson and Company) (NYSE: BDX) has recently launched an innovative tool that is set to transform the landscape of immunology and cancer research. The introduction of the BD® Research Cloud 7.0, featuring the BD Horizon™ Panel Maker, is redefining how scientists approach experimental design in these critical...
Continue Reading
Strategic Partnership Between IONETIX and AlfaRim Medical In a significant move within the medical isotope industry, IONETIX Corporation has announced a strategic partnership with AlfaRim Medical B.V. This collaboration sets the stage for accelerating the commercial production of Actinium-225, a crucial isotope used in targeted alpha therapies for various cancers. As...
Continue Reading
Endeavour Silver's Terronera Project Update: Key Developments Endeavour Silver Corp. (NYSE: EXK; TSX: EDR) has unveiled a significant third-quarter construction progress report for its Terronera Project located in Mexico. The company takes pride in its remarkable strides toward achieving full operational readiness. Progress Overview The Terronera Project has progressed...
Continue Reading
Significant Rise in Healthcare Data Breaches In the healthcare industry, data breaches hit a dramatic peak, leading to an alarming tally of over 276 million records compromised. This stunning figure represents a staggering 64.1% increase from prior years, illustrating profound vulnerabilities in the protection of sensitive patient information. As such, the harsh reality...
Continue Reading
Understanding the Tempus AI Class Action Lawsuit Investors in Tempus AI, Inc. (NASDAQ: TEM) may find themselves in a position to lead a class action lawsuit following substantial financial losses. This legal opportunity arises from significant allegations against the company, which purports to be advancing precision medicine through artificial intelligence. Who Can...
Continue Reading
